1. Introduction {#sec0005}
===============

An inflammatory hepatic pseudotumor (IHPT) is a rare benign lesion whose etiology is unclear. IHPT may mimic malignant tumors when found in a patient with a history of malignancy. Some cases of IHPT have been associated with malignant tumors. We, herein, report a case of resected multiple IHPT incorrectly diagnosed as metastatic liver tumors, occurring after colonic cancer. Our case report was based on the SCARE Guidelines [@bib0005].

2. Presentation of case {#sec0010}
=======================

The patient was a 67-year-old man who had undergone left hemicolectomy for descending colonic cancer (T3 N0 M0 stage IIA) 2 years prior to presentation. He underwent adjuvant chemotherapy with oral uracil and tegafur plus leucovorin for 6 months. One year after the hemicolectomy, the patient was found to have cholecystolithiasis and required cholecystectomy. He was otherwise clinically well without obvious tumor (colonic cancer) recurrence.

Blood chemistry analysis determined the levels of hepatobiliary enzymes.

The laboratory findings on admission were as follows: **a**spartate aminotransferase 34 U/L, alanine aminotransferase 29 U/L, alkaline phosphatase ALP 392 U/L, and γ-glutamyltransferase 37 U/L. However, the carcinoembryonic antigen level was marginally elevated (7.0 ng/mL) ([Table 1](#tbl0005){ref-type="table"}). Sonazoid-enhanced ultrasonography showed that the tumors were hypoechoic at the post-vascular phase and were detected at the Kupffer phase. Computed tomography (CT) revealed two irregular peripherally enhanced S6 tumors protruding from the liver surface ([Fig. 1](#fig0005){ref-type="fig"}a and b). Moreover, the tumors appeared to be growing extrahepatically. Magnetic resonance imaging (MRI) could not be performed because the patient had a tattoo. Fluorodeoxyglucose positron emission tomography (PET-CT) confirmed abnormal metabolic activity in the S6 lesion, with a high standardized uptake value of 4.27 ([Fig. 2](#fig0010){ref-type="fig"}). Percutaneous needle biopsy under ultrasonic guidance was not attempted owing to a risk of tumor cell dissemination.Fig. 1a and b. Preoperative abdominal CT findings. Abdominal CT revealed two irregular peripherally enhanced S6 tumors protruding from the liver surface (black arrow). CT, computed tomography.Fig. 2Preoperative PET-CT. Fluorodeoxyglucose positron emission tomography confirmed abnormal metabolic activity in the S6 lesion, with a high standardized uptake value of 4.27 (white arrow). PET-CT, fluorodeoxyglucose positron emission tomography.Table 1Laboratory findings.VariableRangeOn admissionPeripheral bloodWBC (/ul)3900--98008200RBC (/ul)430--570585×10^4^Hb (g/dl)13.5--17.617.4Hct (%)40.0--52.051.2Plt (/ul)12.0--34.023.2 × 10^4^  Tumor markersCEA0−57.0 ng/mlCA19-90−374U/ml  Blood chemistryTP (g/dl)6.5--8.38.0ALB (g/dl)3.8--5.24.5T.Bil (mg/dl)0.2--1.20.8AST (IU/l)10--4034ALT (IU/l)5--4529ALP (IU/l)110--340392γ-GTP (U/l)12--8737LDH (IU/l)107--230169BUN (mg/dl)8.0--20.016.0Cr (mg/dl)0.61--1.04.070Na (mEq/l)135--147142K (mEq/l)3.3--5.04.1Cl (mEq/l)98--108103CPK (IU/l)45--19071  Serological testsCRP (mg/dl)0--0.300.11HBsAg(-)HBsAb(-)HCVAb(-)  CoagulationPT (sec)10.5--13.510.8PT (%)70--130104.6apTT(sec)25--4035.5　

This patient was admitted to the Division of Surgery of the Gastroenterological Center in our hospital and underwent S6 partial hepatectomy because of suspected malignancy. He had an unremarkable postoperative course and was discharged in remission from our hospital 7 days after surgery.

The resected specimen showed that the tumor was located in the segment 6 area of the liver. The cut surface was yellowish and the white tumor measured 15 mm × 13 mm ([Fig. 3](#fig0015){ref-type="fig"}). Histological examination of the tumor did not reveal any malignant cells. However, a remarkable infiltration of inflammatory cells was observed ([Fig. 4](#fig0020){ref-type="fig"}).Fig. 3Macroscopic findings of the resected specimen. The resected specimen showed that the tumor was located in the S6 area of the liver. The cut surface was yellowish and the white tumor measured 15 mm × 13 mm in diameter (black arrow).Fig. 4Histological appearance (hematoxylin-eosin staining × 40). No malignant cells were identified in the tumor. However, a remarkable infiltration of inflammatory cells was observed (black arrow).

The patient was finally diagnosed with IHPT of the fibrohistiocytic type. The patient was managed with adjuvant chemotherapy for 6 months, and to date, no recurrence or metastasis has been noted after 4 years.

3. Discussion {#sec0015}
=============

Inflammatory pseudotumors are benign lesions mostly occurring in the lungs [@bib0010] and are also referred to as inflammatory myoblastic tumors. They are characterized by localized fibrous proliferations with chronic inflammatory cell infiltration. Histologically, inflammatory pseudotumors are characterized by bland spindle cells and numerous inflammatory cells with a background of collagenous, hyalinized, or myxoid stroma [@bib0015]. The liver is the second most common organ for inflammatory pseudotumors. However, the pathogenesis of IHPT remains largely unknown [@bib0020].

IHPT is also called inflammatory myofibroblastic tumor or plasma cell granuloma and was first described in 1953 by Pack and Becker [@bib0025]. Abdominal pain,　intermittent fever, jaundice, and weight loss are the main symptoms observed in IHPT patients [@bib0030]. IHPT typically presents with non-specific constitutional symptoms such as fever (66%), abdominal pain (51%), and weight loss (21%) [@bib0035], [@bib0040]. However, in this case, physical examination demonstrated no symptoms such as abdominal pain.

According to Kose [@bib0045] and Lopez et al. [@bib0050], IHPT is three times more common in men than in women and is frequently seen in the non-European population. Sixty-one percent of lesions are located in the right hepatic lobe, near the gallbladder, or related to the biliary tree. Yoon et al. [@bib0055] reported that IHPT might result from cholangitis because of the degeneration and necrosis of the bile duct wall with subsequent periductal abscess caused by cholangitis and calculi-associated bile stasis.

Thus, the symptoms and characteristics of IHPT are non-specific and its diagnosis is difficult and may be impossible except by percutaneous needle biopsy preoperatively.

Most importantly, it is difficult to differentiate IHPT from other malignant diseases such as hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic tumor [@bib0060]. Findings on CT, MRI, and PET-CT of IHPT may mimic malignant liver tumors because of non-specific findings. In particular, for patients with malignant tumors and history of malignancy, IHPT is clinically and radiologically difficult to differentiate and may mimic malignant metastatic liver tumors.

We performed a literature search for "inflammatory hepatic pseudotumor" in the Ichushi-Web (Japan Medical Abstracts Society) and PubMed databases from April 2000 to October 2016. During this period, 193 cases of IHPT were reported. Of these, 44 patients (22.8%) had malignant tumors and a history of malignancy, 16 patients (8.3%) had multiple type tumors, and 9 patients (4.7%) had both ([Table 2](#tbl0010){ref-type="table"}).Table 2Cases of multiple inflammatory hepatic pseudotumors with malignant tumors and history of malignancy.CaseUnderlying cancerLocation\
(segment)therapyIgG4-\
relatedPost-biliary diseaseUSCTMRIPETbiopsy1. 75\
maleGastric cancerS3,S5,S6observationnonecholangitisNAdonedoneNAdone2. NACholangio carcinomamultiplePartial resection of the liverNANANAdonedoneNANA3. 62\
maleRectal cancerS5,S7Partial resection of the livernonenonedonedoneNAdoneNA4. 73\
maleGastric cancer GISTS2,S6,S7Partial resection of the liverrelatedcholangitisdonedonedoneNANA5. 48\
femalePancreatic islet cell tumorS4,S8Partial resection of the livernonenonedonedonedoneNAdone6. 57\
femaleSigmoid colon cancerS5,S8Portal vein embolizationNAnonedonedonedoneNANA7. 77\
maleGastric cancerS2,S3observationNAnoneNAdonedoneNANA8. 63\
maleCholangio carcinomaS6,S6observationNAcholangitisdonedoneNANAdone9. 75\
maleGastric cancerS3,S5,S6Partial resection of the liverNAPrimary\
biliary cirrhosisNAdonedoneNANAOur\
case10. 67\
maleDescending colon cancerS6,S6Partial resection of the liverNAcholecystolithiasisdonedoneNAdoneNA

Five of 10 (50%) patients had post-biliary diseases such as cholangitis, cholecystolithiasis, and primary biliary disease, showing that IHPT might result from cholangitis as shown above (10). Over-treatment (resection or percutaneous transhepatic portal embolization) occurred in 7/10 (70%), showing that biopsy before surgery might be important; however, biopsy was performed in only 3 cases. The importance of percutaneous needle biopsy has been reported [@bib0065]. Therefore, percutaneous needle biopsy seems necessary to avoid over-treatment. Because this lesion was located on the surface of the S6 segment, we did not attempt percutaneous needle biopsy because of the risk of tumor cell dissemination.

Moreover, it seems infeasible to perform percutaneous needle biopsy in case of multiple liver tumors. Preoperative examination involved at least two examinations (such as CT and MRI). During examination, it might be important to ascertain lesion size. Repeated imaging studies over the course of a month showed the spontaneous regression of the hepatic tumors. This enabled us to make a diagnosis of IHPT without surgical resection. However, hepatectomy should be considered when a hepatic lesion is suspected to be malignant, in order to rule out malignancy, even if the lesion may be an inflammatory pseudotumor, especially in case of multiple hepatic masses.

4. Conclusion {#sec0020}
=============

IHPT is an important benign liver disease because it is difficult to clinically and radiologically distinguish from malignant tumors. Therefore, knowledge concerning this lesion is important so that treatment can be administered, even by physicians without experience. Percutaneous needle biopsy and adequate follow-up examinations are necessary examinations for cases of suspected single IHPT.
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